• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类星形细胞瘤囊液中的可溶性 Fas 配体(sFasL)对 T 细胞具有细胞毒性:免疫逃逸的另一种潜在方式。

Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.

作者信息

Frankel B, Longo S L, Canute G W

机构信息

Department of Neurosurgery, SUNY Upstate Medical University, Syracuse, NY 13210, USA.

出版信息

J Neurooncol. 2000 May;48(1):21-6. doi: 10.1023/a:1006473800589.

DOI:10.1023/a:1006473800589
PMID:11026693
Abstract

Gliomas of all grades have been shown to express FasL, an apoptosis-inducing protein. Because of the ability of FasL to be cleaved from cell surfaces by metalloproteinases, soluble FasL can be released by FasL bearing cells into surrounding tissues. In the present study, we demonstrate the presence of sFasL in the cyst fluids of astrocytomas. Additionally, a human T-cell line, Jurkat, exposed to astrocytoma cyst fluid resulted in significantly increased cytotoxicity as compared to controls, an effect blocked by FasL neutralizing antibodies. This suggests that sFasL, may be utilized as a means of escaping immune surveillance by these tumors.

摘要

所有级别的胶质瘤均已被证明可表达FasL,一种诱导凋亡的蛋白。由于FasL能够被金属蛋白酶从细胞表面切割下来,可溶性FasL可由表达FasL的细胞释放到周围组织中。在本研究中,我们证实在星形细胞瘤的囊液中存在可溶性FasL。此外,与对照组相比,暴露于星形细胞瘤囊液的人T细胞系Jurkat的细胞毒性显著增加,而FasL中和抗体可阻断这一效应。这表明可溶性FasL可能被这些肿瘤用作逃避免疫监视的一种方式。

相似文献

1
Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.人类星形细胞瘤囊液中的可溶性 Fas 配体(sFasL)对 T 细胞具有细胞毒性:免疫逃逸的另一种潜在方式。
J Neurooncol. 2000 May;48(1):21-6. doi: 10.1023/a:1006473800589.
2
Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer.结肠腺癌细胞释放的可溶性Fas配体诱导宿主淋巴细胞凋亡:结肠癌免疫逃逸的一种活跃模式。
Br J Cancer. 2001 Sep 28;85(7):1047-54. doi: 10.1054/bjoc.2001.2042.
3
Fas/Fas ligand interactions are involved in ultraviolet-B-induced human lymphocyte apoptosis.Fas/Fas配体相互作用参与紫外线B诱导的人淋巴细胞凋亡。
J Immunol. 1998 Jul 1;161(1):241-51.
4
Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells.Jurkat T细胞凋亡诱导中细胞间接触的需求:膜锚定而非可溶性形式的FasL可触发Jurkat T细胞中抗CD3诱导的凋亡。
Biochem Biophys Res Commun. 1997 Sep 18;238(2):670-5. doi: 10.1006/bbrc.1997.7357.
5
Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis.类风湿性关节炎和骨关节炎患者关节中的可溶性Fas配体。
Arthritis Rheum. 1998 Apr;41(4):657-62. doi: 10.1002/1529-0131(199804)41:4<657::AID-ART12>3.0.CO;2-N.
6
Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.从口腔癌患者血清中分离出的Fas配体阳性膜性囊泡可诱导活化T淋巴细胞凋亡。
Clin Cancer Res. 2005 Feb 1;11(3):1010-20.
7
[The "Fas counterattack": a mechanism for immune evasion in human hilar cholangiocarcinomas].["Fas反击”:人类肝门部胆管癌免疫逃逸的一种机制]
Zhonghua Yi Xue Za Zhi. 2002 May 10;82(9):606-9.
8
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.CD7 限制的 Fas 介导的细胞凋亡激活:急性 T 细胞白血病的一种新型治疗方法。
Blood. 2006 Apr 1;107(7):2863-70. doi: 10.1182/blood-2005-07-2929. Epub 2005 Dec 6.
9
Downregulation of Fas ligand by shedding.通过脱落使Fas配体下调。
Nat Med. 1998 Jan;4(1):31-6. doi: 10.1038/nm0198-031.
10
Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.Fas配体在人头颈鳞状细胞癌中表达,并促进T淋巴细胞凋亡。
Cancer Res. 1999 Oct 15;59(20):5356-64.

引用本文的文献

1
Effects of glioblastoma-derived extracellular vesicles on the functions of immune cells.胶质母细胞瘤来源的细胞外囊泡对免疫细胞功能的影响。
Front Cell Dev Biol. 2023 Mar 7;11:1060000. doi: 10.3389/fcell.2023.1060000. eCollection 2023.
2
Immunotherapy of malignant brain tumors.恶性脑肿瘤的免疫治疗
Immunol Rev. 2008 Apr;222:70-100. doi: 10.1111/j.1600-065X.2008.00603.x.
3
Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.

本文引用的文献

1
Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2.共表达Fas和Fas配体的人类星形细胞瘤也产生转化生长因子β2和Bcl-2。
J Neurooncol. 1999;44(3):205-12. doi: 10.1023/a:1006311231189.
2
Co-expression of Fas and Fas ligand in human non-astrocytic glial tumors.Fas与Fas配体在人类非星形胶质细胞性神经胶质瘤中的共表达
Acta Neuropathol. 1999 Oct;98(4):363-6. doi: 10.1007/s004010051095.
3
Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers.
可溶性转化生长因子-β(TGFβ)受体的表达通过调节自然杀伤(NK)细胞对9L胶质肉瘤的体内活性来降低致瘤性。
J Neurooncol. 2003 Aug-Sep;64(1-2):63-9. doi: 10.1007/BF02700021.
人类胶质瘤诱导的免疫抑制涉及可改变单核细胞细胞因子谱和表面标志物的可溶性因子。
J Immunol. 1999 Apr 15;162(8):4882-92.
4
The Fas counterattack: cancer as a site of immune privilege.Fas反击:癌症作为免疫豁免部位
Immunol Today. 1999 Jan;20(1):46-52. doi: 10.1016/s0167-5699(98)01382-6.
5
Cystic lesions accompanying extra-axial tumours.轴外肿瘤伴发的囊性病变。
Neuroradiology. 1999 Jan;41(1):13-7. doi: 10.1007/s002340050696.
6
Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines.Fas与Fas配体在恶性胶质瘤肿瘤及细胞系中的共表达。
Acta Neuropathol. 1998 Mar;95(3):287-90. doi: 10.1007/s004010050799.
7
Human astrocytoma cells are capable of producing macrophage inflammatory protein-1beta.人星形细胞瘤细胞能够产生巨噬细胞炎性蛋白-1β。
J Neurooncol. 1998 Mar;37(1):17-23. doi: 10.1023/a:1005959719927.
8
Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury.
J Neuroimmunol. 1997 Dec;80(1-2):93-6. doi: 10.1016/s0165-5728(97)00139-2.
9
Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.胶质母细胞瘤细胞系和原发性星形细胞脑肿瘤中Fas配体的表达
Brain Pathol. 1997 Jul;7(3):863-9. doi: 10.1111/j.1750-3639.1997.tb00889.x.
10
Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.风湿性疾病中的可溶性Fas(APO-1,CD95)和可溶性Fas配体。
Arthritis Rheum. 1997 Jun;40(6):1126-9. doi: 10.1002/art.1780400617.